Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0 and now includes 3 locations, replacing the previous version v2.9.7.
    Difference
    0.3%
    Check dated 2024-07-23T14:26:36.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T08:26:22.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T14:27:29.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value 'Results First Posted Last Update Posted Revision: v2.9.3' has been updated to 'Results First Posted Last Update Posted Revision: v2.9.5', indicating a revision in the study record details on the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T10:21:29.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value 2023-07-27 for Overall response rate, Disease control rate, Duration of response, 1 year Overall survival, Progression free survival, Change from baseline in tumor-immune microenvironment, T-cell response, and Immune Infiltrate has been updated to reflect detailed assessments and definitions based on RECIST v1.1 criteria. The revision v2.9.1 has recently changed to 2024-06-25 for Results Posted.
    Difference
    24%
    Check dated 2024-06-26T09:20:16.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Genetic and Rare Diseases Information Center resources: Stomach Cancer FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Telomelysin (OBP-301) All patients will receive Telomelysin (OBP-301) at 2x10^12 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks.' This change represents an update in the information provided on the webpage regarding the study details and treatment protocol for the Phase 2 study of Telomelysin (OBP-301) in combination with Pembrolizumab in Esophagogastric Adenocarcinoma.
    Difference
    25%
    Check dated 2024-06-25T08:31:30.000Z thumbnail image

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.